PL384756A1 - Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku - Google Patents

Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku

Info

Publication number
PL384756A1
PL384756A1 PL384756A PL38475608A PL384756A1 PL 384756 A1 PL384756 A1 PL 384756A1 PL 384756 A PL384756 A PL 384756A PL 38475608 A PL38475608 A PL 38475608A PL 384756 A1 PL384756 A1 PL 384756A1
Authority
PL
Poland
Prior art keywords
stable
production method
encapsulated powder
orlistat
composition
Prior art date
Application number
PL384756A
Other languages
English (en)
Other versions
PL216542B1 (pl
Inventor
Jarosław Mazgalski
Anna Szemecka-Gołąbek
Anna Kamińska
Original Assignee
Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna filed Critical Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna
Priority to PL384756A priority Critical patent/PL216542B1/pl
Priority to EP09721857.2A priority patent/EP2268266B1/en
Priority to PCT/PL2009/000025 priority patent/WO2009116880A2/en
Priority to ES09721857T priority patent/ES2836736T3/es
Priority to US12/933,227 priority patent/US20110045085A1/en
Priority to EA201071103A priority patent/EA201071103A1/ru
Priority to PT97218572T priority patent/PT2268266T/pt
Priority to DK09721857.2T priority patent/DK2268266T3/da
Priority to EP20160560.7A priority patent/EP3682869A1/en
Publication of PL384756A1 publication Critical patent/PL384756A1/pl
Publication of PL216542B1 publication Critical patent/PL216542B1/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833Encapsulating processes; Filling of capsules

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL384756A 2008-03-20 2008-03-20 Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku PL216542B1 (pl)

Priority Applications (9)

Application Number Priority Date Filing Date Title
PL384756A PL216542B1 (pl) 2008-03-20 2008-03-20 Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
EP09721857.2A EP2268266B1 (en) 2008-03-20 2009-03-19 Process for obtaining powder compositions of orlistat to be filled into a capsule
PCT/PL2009/000025 WO2009116880A2 (en) 2008-03-20 2009-03-19 Process for obtaining powder compositions of orlistat
ES09721857T ES2836736T3 (es) 2008-03-20 2009-03-19 Proceso para obtener composiciones en polvo de Orlistat para ser llenadas en una cápsula
US12/933,227 US20110045085A1 (en) 2008-03-20 2009-03-19 Process for obtaining powder compositions of orlistat
EA201071103A EA201071103A1 (ru) 2008-03-20 2009-03-19 Способ получения порошковых композиций орлистата
PT97218572T PT2268266T (pt) 2008-03-20 2009-03-19 Processo para obter composições em pó de orlistat a serem preenchidas numa cápsula
DK09721857.2T DK2268266T3 (da) 2008-03-20 2009-03-19 Fremgangsmåde til opnåelse af pulversammensætninger af orlistat, der skal fyldes i en kapsel
EP20160560.7A EP3682869A1 (en) 2008-03-20 2009-03-19 Process for obtaining powder compositions of orlistat

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL384756A PL216542B1 (pl) 2008-03-20 2008-03-20 Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku

Publications (2)

Publication Number Publication Date
PL384756A1 true PL384756A1 (pl) 2009-09-28
PL216542B1 PL216542B1 (pl) 2014-04-30

Family

ID=41055345

Family Applications (1)

Application Number Title Priority Date Filing Date
PL384756A PL216542B1 (pl) 2008-03-20 2008-03-20 Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku

Country Status (8)

Country Link
US (1) US20110045085A1 (pl)
EP (2) EP2268266B1 (pl)
DK (1) DK2268266T3 (pl)
EA (1) EA201071103A1 (pl)
ES (1) ES2836736T3 (pl)
PL (1) PL216542B1 (pl)
PT (1) PT2268266T (pl)
WO (1) WO2009116880A2 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0901602B8 (pt) * 2009-04-03 2021-05-25 Ems S/A formulação farmacêuticas
UA107369C2 (en) * 2010-02-01 2014-12-25 Lab Bago S A Pharmaceutical composition with anti-obesity activity comprising a premixture of pure orlistat and preparation process
WO2012082083A1 (en) * 2010-12-15 2012-06-21 Les Laboratoires Medis Sa Pharmaceutical formulation containing tetrahydrolipstatin as an active ingredient

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6471994B1 (en) * 1995-01-09 2002-10-29 Edward Mendell Co., Inc. Pharmaceutical excipient having improved compressibility
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
TR200100471T2 (tr) 1998-08-14 2001-07-23 F.Hoffmann-La Roche Ag Lipaz inhibitörleri içeren farmasötik bileşimler
AR025587A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
AR025609A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE10021618A1 (de) 2000-05-04 2001-11-15 Volker Helmstaedter Präparat für Darmerkrankungen und dessen Verwendung
PL203804B1 (pl) 2000-06-27 2009-11-30 Hoffmann La Roche Sposób wytwarzania kompozycji farmaceutycznej w postaci spoistej, płytkowej, piankowej, gąbczastej lub ciastowatej struktury i kompozycja farmaceutyczna otrzymana tym sposobem
RU2241462C2 (ru) 2000-07-28 2004-12-10 Ф. Хоффманн-Ля Рош Аг Новая фармацевтическая композиция
US6730319B2 (en) 2001-06-06 2004-05-04 Hoffmann-La Roche Inc. Pharmaceutical compositions having depressed melting points
US20030027786A1 (en) 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
EP1470116A4 (en) * 2001-12-04 2005-04-06 Biogal Gyogyszergyar PREPARATION OF THE ORLISTAT AND CRYSTALLINE FORMS OF THE ORLISTAT
US8372430B2 (en) * 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
US7485322B2 (en) * 2002-12-24 2009-02-03 Lek Pharmaceuticals D.D. Modified release pharmaceutical composition
CL53426B (pl) * 2007-08-06 2016-11-28
EA201070378A1 (ru) 2007-09-17 2010-08-30 Др. Редди`С Лабораторис Лтд. Фармацевтические составы орлистата
WO2009044380A2 (en) 2007-10-05 2009-04-09 Ranbaxy Laboratories Limited Formulations containing orlistat particles having controlled particle size

Also Published As

Publication number Publication date
WO2009116880A2 (en) 2009-09-24
DK2268266T3 (da) 2020-11-02
PT2268266T (pt) 2020-12-18
EP2268266A2 (en) 2011-01-05
EP2268266B1 (en) 2020-10-21
EA201071103A1 (ru) 2011-02-28
EP3682869A1 (en) 2020-07-22
PL216542B1 (pl) 2014-04-30
ES2836736T3 (es) 2021-06-28
US20110045085A1 (en) 2011-02-24
WO2009116880A3 (en) 2009-12-10

Similar Documents

Publication Publication Date Title
PL2252419T3 (pl) Kompozycja ferromagnetycznego proszku i sposób jej wytwarzania
PL2525667T3 (pl) Sposób formowania i wymiarowania gumy do żucia
AP3776A (en) Production of encapsulated nanoparticles at commercial scale
PL2459641T3 (pl) Kompozycje fluoropolimeru zawierającego związek poliolu oraz sposoby ich wytwarzania
SI2415743T1 (sl) Piceatanol vsebujoč sestavek in postopek proizvodnje piceatanol vsebujočega sestavka
PL2207907T3 (pl) Kompozycja metalurgii proszkowej i sposób wytwarzania
PL2402136T3 (pl) Urządzenie do formowania osadowego z proszku i sposób formowania osadowego z proszku
EP2399967A4 (en) PROCESS FOR PRODUCING A POWDER COATING COMPOSITION
PL2406176T3 (pl) Mikronizowany proszek siarki i sposób jego wytwarzania
PL2243725T3 (pl) Element opakowaniowy i sposób jego wytwarzania
EP2499201A4 (en) POLYMER COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF AND ARTICLES THEREOF
PL2513918T3 (pl) Kompozycja proszku ferromagnetycznego i sposób jej produkcji
ZA201303617B (en) Method of sintering a composition
ZA200808848B (en) Method of preparing a pulverulent composition and product as obtained
TWI372666B (en) Preparing composition of silver nanowire and method for forming silver nanowire
IL208669A0 (en) Method of producing a dry earthworm powder
GB2465115B (en) A novel powder and its method of manufacture
PL384756A1 (pl) Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
ZA201304127B (en) Oral compositions and method for producing thereof
PT2413717E (pt) Composições de chocolate dietético e método de produção das mesmas
GB2479721B (en) Method of producing a powder
ZA201304126B (en) Oral compositions and method for producing thereof
GB0814927D0 (en) Modification of plant theronine production
PL385356A1 (pl) Sposób wytwarzania tadalafilu
ZA201304088B (en) Oral compositions and method for producing thereof